Neumora Therapeutics, Inc.
NMRA
$1.20
-$0.05-4.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 19.41% | 10.08% | -4.75% | -7.63% | 22.45% |
| Total Depreciation and Amortization | -12.50% | -11.11% | -60.87% | 21.05% | -87.90% |
| Total Amortization of Deferred Charges | -5.74% | -65.43% | -- | -- | -- |
| Total Other Non-Cash Items | -2.00% | 4.60% | 25.85% | -26.19% | -14.62% |
| Change in Net Operating Assets | -434.90% | -123.84% | -28.42% | 158.96% | -1,348.38% |
| Cash from Operations | 14.82% | 3.23% | -2.83% | 11.01% | 11.85% |
| Capital Expenditure | -- | -- | 200.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -100.00% | 51.06% | -45.98% | 3.57% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -16.90% | 69.06% | -31.36% |
| Cash from Investing | -100.00% | -99.83% | -16.90% | 68.82% | -31.17% |
| Total Debt Issued | -- | -- | 28,702.21% | -100.74% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -10.48% | -45.27% | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -14.57% | -81.50% | 43,311.76% | -100.74% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 14.72% | -166.33% | 1,075.44% | 228.11% | 76.78% |